Skip to content
Open access · CC-BY via OpenAlex

ALKBH5‐mediated m 6 A demethylation ameliorates extracellular matrix deposition in cutaneous pathological fibrosis

Ruoqing Xu, En Yang, Hsin Liang, Shenying Luo, Yunhan Liu, Yimin Khoong, Haizhou Li, Xin Huang, Yixuan Zhao, Tao Zan

Clinical and Translational Medicine · 2024 · ▲ 16 citations

Abstract

Abstract Background Elevated extracellular matrix (ECM) accumulation is a major contributing factor to the pathogenesis of fibrotic diseases. Recent studies have indicated that N6‐methyladenosine (m 6 A) RNA modification plays a pivotal role in modulating RNA stability and contribute to the initiation of various pathological conditions. Howbeit, the precise mechanism by which m 6 A influences ECM deposition remains unclear. Methods In this study, we used hypertrophic scars (HTSs) as a paradigm to investigate ECM‐related diseases. We focused on the role of ALKBH5‐mediated m 6 A demethylation within the pathological progression of HTSs and examined its correlation with clinical stages. The effects of ALKBH5 ablation on ECM components were studied both in vivo and in vitro. Downstream targets of ALKBH5, along with their underlying mechanisms, were identified using integrated high‐throughput analysis, RNA‐binding protein immunoprecipitation and RNA pull‐down assays. Furthermore, the therapeutic potential of exogenous ALKBH5 overexpression was evaluated in fibrotic scar models. Results ALKBH5 was decreased in fibroblasts derived from HTS lesions and was negatively correlated with their clinical stages. Importantly, ablation of ALKBH5 promoted the expression of COL3A1, COL1A1, and ELN, leading to pathological deposition and reconstruction of the ECM both in vivo and in vitro. From a therapeutic perspective, the exogenous overexpression of ALKBH5 significantly inhibited abnormal collagen deposition in fibrotic scar models. As determined by integrated high‐throughput analysis, key ECM components including COL3A1, COL1A1, and ELN are direct downstream targets of ALKBH5. By means of its mechanism, ALKBH5 inhibits the expression of COL3A1, COL1A1, and ELN by removing m 6 A from mRNAs, thereby decreasing their stability in a YTHDF1‐dependent manner. Conclusions Our study identified ALKBH5 as an endogenous suppressor of pathological ECM deposition, contributing to the development of a reprogrammed m6A‐targeted therapy for HTSs.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1002/ctm2.70016
Canonical
link ↗
Fetched
2026-11-14 MST

Cite this

APA
Xu, R., Yang, E., Liang, H., Luo, S., Liu, Y., Khoong, Y., Li, H., Huang, X., Zhao, Y., &amp; Zan, T. (2024). ALKBH5‐mediated m 6 A demethylation ameliorates extracellular matrix deposition in cutaneous pathological fibrosis. <em>Clinical and Translational Medicine</em>. https://doi.org/10.1002/ctm2.70016
Vancouver
Xu R, Yang E, Liang H, Luo S, Liu Y, Khoong Y, et al. ALKBH5‐mediated m 6 A demethylation ameliorates extracellular matrix deposition in cutaneous pathological fibrosis. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.70016.
BibTeX
@article{ruoqing2024ALKBHm, title = {ALKBH5‐mediated m 6 A demethylation ameliorates extracellular matrix deposition in cutaneous pathological fibrosis}, author = {Ruoqing Xu and En Yang and Hsin Liang and Shenying Luo and Yunhan Liu and Yimin Khoong and Haizhou Li and Xin Huang and Yixuan Zhao and Tao Zan}, journal = {Clinical and Translational Medicine}, year = {2024}, doi = {10.1002/ctm2.70016}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings